Your browser doesn't support javascript.
loading
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.
Baldini, C; Charton, E; Schultz, E; Auroy, L; Italiano, A; Robert, M; Coquan, E; Isambert, N; Moreau, P; Le Gouill, S; Le Tourneau, C; Ghrieb, Z; Kiladjian, J J; Delord, J P; Roca, C Gomez; Vey, N; Barlesi, F; Lesimple, T; Penel, N; Soria, J C; Massard, C; Besle, S.
Afiliação
  • Baldini C; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif; Laboratory for Immunomonitoring in Oncology (LIO), University Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif. Electronic address: capucine.baldini@gustaveroussy.fr.
  • Charton E; Human and Social Sciences Department, Centre Léon Bérard, Lyon.
  • Schultz E; CEPED (UMR 196), Université de Paris, IRD, Paris; SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, CANBIOS Team (Équipe Labellisée LIGUE 2019), Aix-Marseille University, INSERM, IRD, Marseille.
  • Auroy L; Université Grenoble Alpes, CNRS, Sciences Po Grenoble, Pacte, Grenoble.
  • Italiano A; Institut Bergonié, Early Phase Trials and Sarcoma Units, Bordeaux; University of Bordeaux, Bordeaux.
  • Robert M; Institut de Cancérologie de l'Ouest, Medical Oncology Department, Saint-Herblain.
  • Coquan E; François Baclesse Cancer Center, Department of Oncology, Caen.
  • Isambert N; Département d'Innovations Thérapeutiques/recherche Translationnelle en Oncologie et Hématologie (DITTOH), INSERM U1084, CHU de Poitiers, Poitiers.
  • Moreau P; Centre GF Leclerc, Medical Oncology Department, Dijon.
  • Le Gouill S; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.
  • Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, Paris & Saint-Cloud.
  • Ghrieb Z; APHP, Hopital Saint-Louis, Centre d'Investigations Cliniques, Paris.
  • Kiladjian JJ; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
  • Delord JP; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
  • Roca CG; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
  • Vey N; Aix-Marseille University, CNRS, Inserm, Institut Paoli-Calmettes, Hematology Department, CRCM, Marseille.
  • Barlesi F; Aix Marseille University, CNRS, INSERM, CRCM, APHM, Marseille Early Phases Cancer Center CLIP(2), Marseille; Gustave Roussy, Université Paris-Saclay, Villejuif.
  • Lesimple T; Clinical Research Department, CLIP(2) and ARPEGO Network, Rennes.
  • Penel N; CLIP(2) Lille, Centre Oscar Lambret, Lille and Lille University, Lille.
  • Soria JC; Gustave Roussy, Université Paris-Saclay, Villejuif.
  • Massard C; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif.
  • Besle S; Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif; Laboratory for Immunomonitoring in Oncology (LIO), University Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif; Lyon 1 University, EA4129, Lyon, France.
ESMO Open ; 7(3): 100468, 2022 06.
Article em En | MEDLINE | ID: mdl-35533427

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: ESMO Open Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: ESMO Open Ano de publicação: 2022 Tipo de documento: Article